181816-48-8

Basic information

• Product Name: Ombrabulin
• Synonyms: ombrabulin;(2S)-2-Amino-3-hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide;PropanaMide,2-aMino-3-hydroxy-N-[2-Methoxy-5-[(1Z)-2-(3,4,5-triMethoxyphenyl)ethenyl]phenyl]-,(2S)-;AVE-8062;OMbrabulin(AVE-8062)
• CAS NO: 181816-48-8
• Molecular Formula: C21H26N2O6
• Molecular Weight: 402.44
• Mol File: 181816-48-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 648.1 °C at 760 mmHg
• Flash Point: 345.8 °C
• Appearance: /
• Density: 1.258
• Storage Temp.: 2-8°C
• PKA: 12.03±0.10(Predicted)
• CAS DataBase Reference: Ombrabulin(CAS DataBase Reference)
• NIST Chemistry Reference: Ombrabulin(181816-48-8)
• EPA Substance Registry System: Ombrabulin(181816-48-8)

Safety Data

• Hazardous Substances Data: 181816-48-8(Hazardous Substances Data)

Usage

Description

Ombrabulin is a novel vascular disrupting agent that selectively targets and disrupts the abnormal blood vessels in solid tumors, leading to rapid cell death and tumor shrinkage. It has shown promising results in enhancing the efficacy of standard therapies in head and neck squamous cell carcinomas.

Uses

Used in Oncology:
Ombrabulin is used as a vascular disrupting agent for enhancing the standard therapies in head and neck squamous cell carcinomas. It selectively targets and disrupts the abnormal blood vessels in solid tumors, leading to rapid cell death and tumor shrinkage.
Used in Drug Delivery Systems:
While the provided materials do not mention specific drug delivery systems for Ombrabulin, it is worth noting that drug delivery systems can be developed to improve the delivery, bioavailability, and therapeutic outcomes of Ombrabulin, similar to the approach taken with Gallotannin. These systems may involve various organic and metallic nanoparticles as carriers for Ombrabulin delivery, aiming to enhance its efficacy against cancer cells.

Upstream product

• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 21852-50-6 3,4,5-trimethoxybenzyl bromide 
• 3840-31-1 (3,4,5-trimethoxyphenyl)methanol 
• 61240-20-8 triphenyl-(3,4,5-trimethoxybenzyl)phosphonium bromide 
• 313673-23-3 (4-methoxy-3-nitrobenzyl)triphenylphosphonium bromide 
• 162705-13-7 (Z)-1-(4''-methoxy-3''-nitrophenyl)-2-(3',4',5'-trimethoxyphenyl)ethene 
• 162705-07-9 3-amino-deoxycombretastatin A₄ 
• 61010-34-2 3-nitro-4-methoxybenzyl bromide 
• 119-10-8 4-methoxy-3-nitrotoluene 
• 286463-65-8 (S,Z)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((2-methoxy-5-(3,4,5-trimethoxystyryl)phenyl)amino)-3-oxopropyl acetate 

Relevant articles and documents

Compositions and Methods for Treatment of Cancer

Resistance of randomly dispersed and oxygen-starved lung tumor cells to chemo- and radiotherapy constitutes the vast majority recurrences and death from lung cancer. We use sickle cells derived from humans with sickle cell anemia to target oxygen-deprived

Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents

Targeting tumor vasculature represents an intriguing therapeutic strategy in the treatment of cancer. In an effort to discover new vascular disrupting agents with improved water solubility and potentially greater bioavailability, various amino acid prodru

Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents

A series of analogs with nitro or serinamide substituents at the C-2′-, C-5′-, or C-6′-position of the combretastatin A-4 (CA4) B-ring was synthesized and evaluated for cytotoxic effects against heart endothelioma cells, blood flow reduction to tumors in